在临床实践中APOL1测试和新疗法的机会
Taewoo Lee1, Lijun Ma, Barry I Freedman
1Department of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
针对阿波利波蛋白L1 (APOL1) 基因的新型疗法在治疗APOL1介导病 (AMKD) 方面表现有前途. 随着这些有效的治疗方法的开发,预计APOL1基因型的增加将对高危人群产生影响.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 2010年发现的阿波利波蛋白L1 (APOL1) 基因变异与近期非洲血统个体的病有关.
- 高风险的APOL1基因型显著增加了对各种病的易感性,包括FSGS和狼性炎.
- APOL1风险变体也与非洲裔美国捐赠者的加速移植失败有关.
研究的目的:
- 审查针对APOL1.1的新型治疗策略.
- 讨论APOL1基因定型对APOL1介导病 (AMKD) 患者的不断变化的场景.
主要方法:
- 对AMKD当前和新兴治疗方法的审查.
- 对APOL1基因定型增加的影响的分析.
主要成果:
- 现有的治疗方法,如RAAS阻塞和SGLT2抑制剂,可以减缓进展,但不能治愈.
- 临床试验正在评估针对APOL1的治疗方法,包括小分子抑制剂,反感性寡核酸和JAK抑制剂.
- 这些新型疗法的早期试验结果是有希望的,表明了耐受性良好和有效治疗的潜力.
结论:
- 虽然APOL1毒性的确切机制仍在调查中,但向疗法为AMKD提供了重要的希望.
- 成功的临床试验可能需要更广泛的APOL1基因定型,并改变危险人群中慢性病的诊断和治疗范式.
更多相关视频
10:16In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
相关概念视频
Preclinical Development: Overview
Clinical Trials: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drug Therapy
Antianxiety Medications
Clinical Trials
There are four phases in a clinical trial. A phase one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
